FOXO4-DRI: Dosing Protocols

Research Dosing Disclaimer#

The dosing information below is derived exclusively from preclinical mouse studies and is provided for educational and research reference purposes only. FOXO4-DRI is not approved for human use by any regulatory agency. No human dosing protocols have been established, and no human dose-finding or pharmacokinetic studies have been conducted. The translation of mouse dosing to human-equivalent doses involves substantial uncertainty and should not be attempted without formal preclinical development and regulatory oversight.

Preclinical Dosing Protocol#

Baar et al. 2017 Cell Study Protocol#

The only published dosing protocol for FOXO4-DRI comes from the 2017 Cell paper by Baar, Brandt, Putavet et al. In this foundational study, the peptide was administered to mice using the following regimen:

• Dose: 5 mg/kg body weight
• Route: Intravenous (IV) injection
• Frequency: Three times per week
• Duration: Several weeks (the exact number of weeks varied across experimental cohorts and models within the study)
• Species: Mice, including naturally aged mice (over 24 months) and doxorubicin-treated mice

This protocol was applied in two principal experimental contexts:

Naturally aged mice: Mice over 24 months old received FOXO4-DRI at 5 mg/kg IV three times per week. Outcome measures included fur density restoration, exploratory behavior, renal function (serum creatinine and urea nitrogen), and tissue markers of senescence (p16INK4a expression, senescence-associated beta-galactosidase activity). Improvements across these endpoints were reported in treated versus control animals.

Chemotherapy-induced senescence model: Mice treated with doxorubicin to induce widespread cellular senescence received subsequent FOXO4-DRI treatment at 5 mg/kg IV three times per week. This arm demonstrated that FOXO4-DRI could clear chemotherapy-induced senescent cells and improve recovery outcomes.

No Additional Published Dosing Studies#

As of the current literature, no other research groups have published independent dosing studies for FOXO4-DRI. The Baar et al. protocol remains the sole published reference for dose selection, route, and frequency. No dose-response studies exploring alternative doses, frequencies, or durations have been published. No studies have evaluated subcutaneous, intramuscular, intraperitoneal, or other routes of administration for FOXO4-DRI.

Rationale for Intermittent Dosing#

The three-times-per-week intermittent schedule used in the Baar et al. study reflects a principle that has been discussed more broadly in the senolytic field. Senolytic agents are generally conceived as intermittent rather than continuous therapies, for several reasons.

Hit-and-Run Senolytic Concept#

Senescent cells, once eliminated, are not rapidly replaced by new senescent cells. The accumulation of senescent cells occurs over weeks, months, or years, driven by ongoing cellular stress, DNA damage, and aging processes. A senolytic agent needs only to be present long enough to trigger the apoptotic cascade in existing senescent cells. Once apoptosis has been initiated (a process that proceeds to completion over hours), the continued presence of the senolytic agent is not required.

This "hit-and-run" pharmacological concept means that periodic rather than continuous administration may be sufficient to achieve therapeutic benefit. Between treatment periods, tissues can clear apoptotic debris and potentially undergo regenerative recovery without the ongoing presence of the drug.

Allowing Recovery Between Treatments#

Intermittent dosing also provides recovery windows during which any acute effects of senescent cell clearance -- including transient inflammation from apoptotic debris, temporary disruption of tissue homeostasis, or other transient perturbations -- can resolve before the next treatment cycle. This is particularly relevant given the theoretical concern that rapid, extensive senescent cell clearance could transiently overwhelm the tissue's capacity for debris management.

Precedent from Other Senolytics#

The intermittent dosing concept is not unique to FOXO4-DRI. Dasatinib plus quercetin, the most clinically advanced senolytic combination, has also been administered using intermittent schedules in human clinical trials (for example, three consecutive days per week or three consecutive days every two weeks). The senolytic field as a whole has adopted the principle that these agents should be given periodically rather than continuously, in contrast to most conventional chronic disease medications.

Administration Route Considerations#

Intravenous Administration in Mice#

The Baar et al. study used intravenous injection as the route of administration. In mice, this is typically performed via tail vein injection. The IV route ensures complete systemic bioavailability, bypasses absorption variables, and provides rapid distribution to tissues.

Challenges for Alternative Routes#

FOXO4-DRI is a peptide of approximately 4826.5 Da molecular weight. Several route-specific considerations apply:

• Oral administration: Not feasible. The peptide's size precludes meaningful intestinal absorption. While the D-amino acid composition confers resistance to gastrointestinal proteases (unlike L-amino acid peptides), the molecular weight is the primary barrier to oral bioavailability rather than proteolytic degradation alone.
• Subcutaneous injection: Not tested for FOXO4-DRI. Subcutaneous administration is commonly used for peptide therapeutics in general and could theoretically be evaluated, but absorption kinetics, local tissue reactions, and bioavailability via this route have not been characterized for FOXO4-DRI.
• Intramuscular injection: Not tested. Similar to subcutaneous administration, intramuscular delivery is feasible for peptides but has not been evaluated for FOXO4-DRI.
• Intranasal or pulmonary delivery: Not tested. These routes are used for some peptides targeting specific organs but have not been explored for FOXO4-DRI.

Intracellular Delivery Requirements#

A unique pharmacological challenge for FOXO4-DRI is that its molecular target -- the FOXO4-p53 complex -- is located inside the cell, specifically within PML nuclear bodies in the nucleus. The peptide must therefore cross both the plasma membrane and the nuclear membrane to reach its target. The mechanisms by which FOXO4-DRI achieves intracellular and nuclear access have not been fully elucidated. The efficiency of cell penetration may vary across different tissue types and could limit efficacy in tissues with high barriers to peptide uptake, such as dense fibrotic lesions where senescent cells are often concentrated.

Absence of Human Dosing Information#

No human dosing data exist for FOXO4-DRI. The following key gaps prevent any evidence-based translation to human protocols:

• No human pharmacokinetic studies: Plasma half-life, volume of distribution, clearance rate, and tissue distribution in humans are entirely unknown.
• No allometric dose conversion: While standard body surface area scaling methods can provide rough estimates of human-equivalent doses from mouse data, such conversions require pharmacokinetic validation that does not exist for FOXO4-DRI. A naive body surface area conversion of the 5 mg/kg mouse dose would yield a substantially lower per-kilogram dose in humans, but this calculation carries high uncertainty.
• No dose-response characterization: Even in mice, only a single dose level (5 mg/kg) has been reported. Without dose-response data, the therapeutic window -- the range between effective and toxic doses -- cannot be estimated.
• No safety dose escalation: No maximum tolerated dose or dose-limiting toxicity studies have been conducted in any species.
• No biomarker-guided dosing: There are no established biomarkers of FOXO4-DRI engagement or efficacy that could guide dose selection in humans.

Reconstitution and Handling#

No specific reconstitution or handling instructions for FOXO4-DRI have been published in the peer-reviewed literature. Research-grade peptides are typically supplied as lyophilized powder and reconstituted in sterile water, bacteriostatic water, or buffered saline according to the manufacturer's instructions. Standard peptide handling precautions (avoidance of repeated freeze-thaw cycles, storage of reconstituted solutions at 2-8 degrees Celsius, protection from light) would apply in the absence of compound-specific guidance.

Evidence Gaps in Dosing#

• Only a single dose level has been tested in published studies
• No dose-response or dose-escalation studies have been performed in any species
• No pharmacokinetic parameters have been published for FOXO4-DRI
• Alternative routes of administration have not been evaluated
• Optimal treatment duration and interval between treatment cycles are unknown
• Whether intermittent dosing is superior to alternative schedules has not been tested
• Human-equivalent dosing cannot be estimated with any confidence from existing data

Related Reading#

• FOXO4-DRI overview and research guide
• FOXO4-DRI side effects profile
• FOXO4-DRI research evidence